Cargando…

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma

SIMPLE SUMMARY: Lactate dehydrogenase (LDH) levels prior to treatment are a known biomarker to predict advanced melanoma’s response to immune checkpoint inhibitors (ICI). In this study, we evaluated the ability of machine learning-based models to predict responses to ICI and complement LDH for in pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabari, Azadeh, Cox, Meredith, D’Amore, Brian, Mansur, Arian, Dabbara, Harika, Boland, Genevieve, Gee, Michael S., Daye, Dania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216156/ https://www.ncbi.nlm.nih.gov/pubmed/37345037 http://dx.doi.org/10.3390/cancers15102700

Ejemplares similares

Machine Learning-Based Radiomic Features on Pre-Ablation MRI as Predictors of Pathologic Response in Patients with Hepatocellular Carcinoma Who Underwent Hepatic Transplant
por: Tabari, Azadeh, et al.
Publicado: (2023)

Risk stratification with explainable machine learning for 30-day procedure-related mortality and 30-day unplanned readmission in patients with peripheral arterial disease
por: Cox, Meredith, et al.
Publicado: (2022)

Role of Machine Learning in Precision Oncology: Applications in Gastrointestinal Cancers
por: Tabari, Azadeh, et al.
Publicado: (2022)

Role of Machine Learning-Based CT Body Composition in Risk Prediction and Prognostication: Current State and Future Directions
por: Elhakim, Tarig, et al.
Publicado: (2023)

Role of artificial intelligence in risk prediction, prognostication, and therapy response assessment in colorectal cancer: current state and future directions
por: Mansur, Arian, et al.
Publicado: (2023)

Drosophila insulin receptor regulates diabetes-induced mechanical nociceptive hypersensitivity
por: Dabbara, Harika, et al.
Publicado: (2021)

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
por: Pickering, Chad, et al.
Publicado: (2023)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

The Role of Artificial Intelligence in the Detection and Implementation of Biomarkers for Hepatocellular Carcinoma: Outlook and Opportunities
por: Mansur, Arian, et al.
Publicado: (2023)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Metastatic melanoma with spontaneous complete regression of a thick primary lesion
por: Khosravi, Hasan, et al.
Publicado: (2016)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma
por: Wang, Qiyu, et al.
Publicado: (2022)

Two-color immunocytochemistry for evaluation of effusion fluids for metastatic adenocarcinoma
por: Shidham, Vinod B, et al.
Publicado: (2010)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

6. Treatment resistant ulcerating dermatomyositis in metastatic melanoma treated with checkpoint inhibitor therapy
por: Parker, Lucy, et al.
Publicado: (2019)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
por: Sperling, Gabriel, et al.
Publicado: (2022)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p4ngdp2jjdp15hb3kfhirko4jl